Evidence map›Paper›PMID 36462680›Full record

ArticleJournal of hepatology2023

Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.

Jiaqi Sun, Jun Ding, Qingsong Shen, Xiyang Wang, Min Wang, Yongping Huang, Xuechun Zhang, Huan Zhu, Feng Zhang, Dongde Wu and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Jiaqi SunCollege of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Department of Oncology of Renmin Hospital, Wuhan University, Wuhan 430072, China.
Jun DingCAS Key Laboratory of Plant Germplasm Enhancement and Specialty Agriculture, Wuhan Botanical Garden, Chinese Academy of Sciences, Wuhan 430074, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Qingsong ShenCollege of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Department of Oncology of Renmin Hospital, Wuhan University, Wuhan 430072, China.
Xiyang WangCollege of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Department of Oncology of Renmin Hospital, Wuhan University, Wuhan 430072, China.
Min WangCollege of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Department of Oncology of Renmin Hospital, Wuhan University, Wuhan 430072, China.
Yongping HuangCollege of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Department of Oncology of Renmin Hospital, Wuhan University, Wuhan 430072, China.
Xuechun ZhangCollege of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Department of Oncology of Renmin Hospital, Wuhan University, Wuhan 430072, China.
Huan ZhuDepartment of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Wuhan 430079, China.
Feng ZhangDepartment of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Wuhan 430079, China.
Dongde WuDepartment of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Wuhan 430079, China.
Min PengDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Zhonglin ZhangDepartment of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Yufeng YuanDepartment of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Wenhua LiCollege of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Department of Oncology of Renmin Hospital, Wuhan University, Wuhan 430072, China.
Zhi-Gang SheDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Institute of Model Animal of Wuhan University, Wuhan 430071, China.
Xiao-Jing ZhangInstitute of Model Animal of Wuhan University, Wuhan 430071, China; School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China.
Hongliang LiDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Institute of Model Animal of Wuhan University, Wuhan 430071, China; School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China.
Peng ZhangInstitute of Model Animal of Wuhan University, Wuhan 430071, China; School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China. Electronic address: zhp@whu.edu.cn.
Zan HuangCollege of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Department of Oncology of Renmin Hospital, Wuhan University, Wuhan 430072, China. Electronic address: z-huang@whu.edu.cn.
Wuhan University · CNHubei Cancer Hospital · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsAlterations of multiple metabolites characterize distinct features of metabolic reprograming in hepatocellular carcinoma (HCC). However, the role of most metabolites, including propionyl-CoA (Pro-CoA), in metabolic reprogramming and hepatocarcinogenesis remains elusive. In this study, we aimed to dissect how Pro-CoA metabolism affects these processes.

methodsTCGA data and HCC samples were used to analyze ALDH6A1-mediated Pro-CoA metabolism and its correlation with HCC. Multiple metabolites were assayed by targeted mass spectrometry. The role of ALDH6A1-generated Pro-CoA in HCC was evaluated in HCC cell lines as well as xenograft nude mouse models and primary liver cancer mouse models. Non-targeted metabolomic and targeted energy metabolomic analyses, as well as multiple biochemical assays, were performed.

resultsDecreases in Pro-CoA and its derivative propionyl-L-carnitine due to ALDH6A1 downregulation were tightly associated with HCC. Functionally, ALDH6A1-mediated Pro-CoA metabolism suppressed HCC proliferation in vitro and impaired hepatocarcinogenesis in mice. The aldehyde dehydrogenase activity was indispensable for this function of ALDH6A1, while Pro-CoA carboxylases antagonized ALDH6A1 function by eliminating Pro-CoA. Mechanistically, ALDH6A1 caused a signature enrichment of central carbon metabolism in cancer and impaired energy metabolism: ALDH6A1-generated Pro-CoA suppressed citrate synthase activity, which subsequently reduced tricarboxylic acid cycle flux, impaired mitochondrial respiration and membrane potential, and decreased ATP production. Moreover, Pro-CoA metabolism generated 2-methylcitric acid, which mimicked the inhibitory effect of Pro-CoA on citrate synthase and dampened mitochondrial respiration and HCC proliferation.

conclusionsThe decline of ALDH6A1-mediated Pro-CoA metabolism contributes to metabolic remodeling and facilitates hepatocarcinogenesis. Pro-CoA, propionyl-L-carnitine and 2-methylcitric acid may serve as novel metabolic biomarkers for the diagnosis and treatment of HCC. Pro-CoA metabolism may provide potential targets for development of novel strategies against HCC. IMPACT AND IMPLICATIONS: Our study presents new insights on the role of propionyl-CoA metabolism in metabolic reprogramming and hepatocarcinogenesis. This work has uncovered potential diagnostic and predictive biomarkers, which could be used by physicians to improve clinical practice and may also serve as targets for the development of therapeutic strategies against HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAcyl Coenzyme AAnimalsCarnitineCitratesCitrate (si)-SynthaseHumansMice2-methylcitric acidAcyl Coenzyme ACarnitineCitratesCitrate (si)-Synthasepropionyl-coenzyme A2-Methylcitric acidALDH6A1Metabolic reprogrammingPropionyl-CoAPropionyl-L-carnitine

Identifiers

PMID36462680
OpenAlexW4310668501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.